Bioatla Investor Relations Material
Latest events
Q2 2024
Bioatla
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Bioatla Inc
Access all reports
Bioatla Inc is a clinical-stage biopharmaceutical company specializing in the development of novel monoclonal antibody and cell-based therapeutics for the treatment of solid tumor cancers. Utilizing its proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO) platforms, Bioatla is focused on creating therapies with improved selectivity for the tumor microenvironment, potentially enhancing safety and therapeutic efficacy. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
Texas Instruments: From Calculators to Master Capital Allocators
Texas Instruments has undergone many transformations from its origins in oil exploration to become one of the world's largest semiconductor producers.
11 Oct 2024
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Ticker symbol
BCAB
Country
🇺🇸 United States